Locations:
Search
Timing of adjuvant immunotherapy unclear for maximum overall survival
Treatment decision must be balanced against toxicity concerns
Genomic adjusted radiation dose guides treatment decision making
Use of tool can change recommendation to add or omit radiation
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
What is the role of molecular profiling in risk stratification?
Majority of patients achieve complete pathologic response after four-dose cemiplimab therapy
Impressive progression-free survival observed in phase 2 study
Pilot Study at Cleveland Clinic is Testing Feasibility and Biodistribution
Findings support need for personalized disease management
Pathogenic POLE/POLD1 mutations lead to improved response to immune checkpoint blockade therapy
Advertisement
Advertisement